GlassScriptPhysician profile
Syed Azmi
NPI 1922203082
$14,931.74
in general payments reported to CMS, 2019-2025
70 companies · $3,056 in 2025
The $3,056 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,613 · 2020: $710 · 2021: $823 · 2022: $2,415 · 2023: $2,858 · 2024: $3,458 · 2025: $3,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,976 · Education: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,976.01 |
| Education | $395.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,138.28 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $1,084.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,075.74 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,044.32 | 2019-2025 | |
| Celgene Corporation | $924.68 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $786.17 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Gilead Sciences, INC. | $707.41 | 2022-2025 | Trodelvy |
| Lilly USA, LLC | $667.68 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $627.12 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Janssen Biotech, INC. | $587.96 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Glaxosmithkline, LLC. | $447.60 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Abbvie INC. | $424.94 | 2019-2025 | Venclexta |
| Eisai INC. | $382.46 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $368.42 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Incyte Corporation | $325.38 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $324.47 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Daiichi Sankyo INC. | $275.55 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Genentech USA, INC. | $253.60 | 2019-2025 | Tecentriq, Phesgo, Polivy |
| Astellas Pharma US INC | $236.22 | 2019-2025 | Vyloy, Padcev |
| Stemline Therapeutics INC. | $185.08 | 2022-2025 | Orserdu |
| Recordati_rare_diseases_inc. | $179.93 | 2024-2025 | Sylvant, Enjaymo |
| Pharmacyclics LLC, An Abbvie Company | $175.74 | 2021-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $146.64 | 2019-2025 | Libtayo |
| Tempus Ai, INC | $132.02 | 2024-2025 | Xt Cdx |
| Blueprint Medicines Corporation | $128.29 | 2021-2024 | Ayvakit |
| Intuitive Surgical, INC. | $125.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $124.71 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Genzyme Corporation | $112.16 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $107.41 | 2022-2025 | Ultomiris |
| Genmab U.S., INC. | $105.54 | 2023-2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $105.48 | 2021-2025 | |
| Exelixis INC. | $101.59 | 2022-2025 | Cabometyx |
| Taiho Oncology, INC. | $101.56 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $87.13 | 2023-2024 | Orgovyx |
| Mirati Therapeutics, INC. | $85.75 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $78.59 | 2022-2025 | |
| Beigene USA, INC. | $73.72 | 2020-2024 | Brukinsa |
| Array Biopharma INC | $65.34 | 2025 | Braftovi, Mektovi, Tukysa |
| Karyopharm Therapeutics INC. | $64.92 | 2020-2021 | |
| Beone Medicines USA, INC. | $59.29 | 2025 | Tevimbra, Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.35 | 2020-2025 | Gilotrif |
| Puma Biotechnology, INC. | $52.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $51.13 | 2023 | Xarelto |
| Emd Serono, INC. | $49.04 | 2023-2024 | Bavencio |
| Tersera Therapeutics LLC | $48.68 | 2024-2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $42.28 | 2023-2025 | Zepzelca |
| Secura Bio, INC. | $42.27 | 2022 | |
| Biocompatibles, INC. | $41.03 | 2019 | |
| Legend Biotech USA INC. | $37.72 | 2024-2025 | Carvykti |
| Sobi, INC | $33.96 | 2022 | |
| Springworks Therapeutics, INC. | $33.88 | 2024 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $33.29 | 2023 | Empaveli |
| Tesaro, INC. | $32.78 | 2019 | |
| Morphosys, US INC. | $32.12 | 2022-2024 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $31.95 | 2024 | Cosela |
| Geron Corporation | $28.20 | 2025 | Rytelo |
| Adaptive Biotechnologies Corporation | $27.55 | 2024 | Clonoseq |
| Kite Pharma, INC. | $22.95 | 2024 | Yescarta |
| Sanofi US Services INC. | $22.32 | 2025 | |
| Dendreon Pharmaceuticals LLC | $21.97 | 2019 | |
| Syndax Pharmaceuticals, INC. | $21.14 | 2025 | |
| Adc Therapeutics America, INC. | $18.98 | 2023 | |
| Coherus Oncology, INC. | $18.97 | 2021 | |
| Acrotech Biopharma INC. | $17.88 | 2025 | Beleodaq |
| Dova Pharmaceuticals | $16.02 | 2021 | |
| Aveo Pharmaceuticals, INC. | $15.57 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $15.50 | 2021 | |
| Clovis Oncology, INC. | $14.37 | 2019 | |
| Deciphera Pharmaceuticals INC. | $13.38 | 2022 | |
| G1 Therapeutics, INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Azmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.